Sheri McCoy resigns from Johnson & Johnson
pharmafile | April 10, 2012 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Johnson & Johnson, Sheri McCoy, resignation
Johnson & Johnson has announced that Sheri McCoy, vice chairman of the executive committee, will leave the company on April 18, to join Avon Products as it new chief executive.
McCoy had been in the running to become the J&J’s new chief executive, after its current head William Weldon announced his decision to step down last year.
But McCoy lost the race to Alex Gorsky, who will officially take over from Weldon later this month.
Weldon said: “Sheri has made important contributions across Johnson & Johnson throughout her career.
“During these last several years, she was instrumental in helping to bring stronger strategic focus to our pharmaceutical business as it builds a robust pipeline and launches important new medicines; and to our consumer business as it leverages the success of its iconic brands and worked to resolve some recent challenges.”
McCoy began her Johnson & Johnson career in 1982 as a scientist in the consumer R&D organisation and advanced through positions of increasing responsibility in the consumer segment.
In 2005, she became company group chairman for the Ethicon device franchise and a member of the medical device and diagnostics group operating committee.
Three years later, she was named chairman of the surgical care group, and became a member of the Johnson & Johnson executive committee.
She was named worldwide chairman of pharmaceuticals in January 2009.
Related Content
Johnson & Johnson submits robotic surgical system for De Novo classification
Johnson & Johnson has announced the submission of its Ottava Robotic Surgical System for De …
Johnson & Johnson commits $2bn to new manufacturing facility in North Carolina, US
Johnson & Johnson has announced a $2bn investment in a new manufacturing facility in Holly …
Johnson & Johnson submits FDA application for Caplyta to prevent schizophrenia relapse
Johnson & Johnson has submitted a supplemental New Drug Application to the US Food and …
